KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ginkgo Bioworks Holdings (DNA) Other Non-Current Liabilities (2020 - 2025)

Ginkgo Bioworks Holdings' Other Non-Current Liabilities history spans 6 years, with the latest figure at $22.9 million for Q4 2025.

  • For Q4 2025, Other Non-Current Liabilities rose 38.01% year-over-year to $22.9 million; the TTM value through Dec 2025 reached $22.9 million, up 38.01%, while the annual FY2025 figure was $22.9 million, 38.01% up from the prior year.
  • Other Non-Current Liabilities reached $22.9 million in Q4 2025 per DNA's latest filing, up from $17.2 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $212.9 million in Q3 2021 to a low of $12.3 million in Q3 2023.
  • Average Other Non-Current Liabilities over 5 years is $45.9 million, with a median of $24.7 million recorded in 2023.
  • Peak YoY movement for Other Non-Current Liabilities: surged 1087.07% in 2021, then plummeted 81.34% in 2022.
  • A 5-year view of Other Non-Current Liabilities shows it stood at $36.0 million in 2021, then fell by 13.34% to $31.2 million in 2022, then decreased by 21.67% to $24.4 million in 2023, then plummeted by 32.16% to $16.6 million in 2024, then skyrocketed by 38.01% to $22.9 million in 2025.
  • Per Business Quant, the three most recent readings for DNA's Other Non-Current Liabilities are $22.9 million (Q4 2025), $17.2 million (Q3 2025), and $17.9 million (Q2 2025).